JP2012525422A5 - - Google Patents

Download PDF

Info

Publication number
JP2012525422A5
JP2012525422A5 JP2012508721A JP2012508721A JP2012525422A5 JP 2012525422 A5 JP2012525422 A5 JP 2012525422A5 JP 2012508721 A JP2012508721 A JP 2012508721A JP 2012508721 A JP2012508721 A JP 2012508721A JP 2012525422 A5 JP2012525422 A5 JP 2012525422A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
amount
centerkin
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2012508721A
Other languages
English (en)
Other versions
JP2012525422A (ja
JP5498571B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/032942 external-priority patent/WO2010127096A2/en
Publication of JP2012525422A publication Critical patent/JP2012525422A/ja
Publication of JP2012525422A5 publication Critical patent/JP2012525422A5/ja
Application granted granted Critical
Publication of JP5498571B2 publication Critical patent/JP5498571B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Claims (9)

  1. 治療有効量のセンタキンを含有する出血性ショック蘇生を治療するための医薬組成物。
  2. 治療有効量のセンタキンを含有する循環障害に起因するショックを治療するための医薬組成物。
  3. 前記センタキンの治療有効量が、０.０５〜０.４５ｍｇ/ｋｇである請求項１または２に記載の医薬組成物。
  4. 前記センタキンの治療有効量が、０.０５〜０.１５ｍｇ/ｋｇである請求項１または２に記載の医薬組成物。
  5. 乳酸リンゲル液をさらに含む請求項１乃至４のいずれかに記載の医薬組成物。
  6. 前記乳酸リンゲル液の量が、喪失した血液の量の１００％以下である請求項５に記載の医薬組成物。
  7. 前記乳酸リンゲル液の量が、喪失した血液の量の３００％以下である請求項５に記載の医薬組成物。
  8. 出血性ショック蘇生の治療剤を製造するためのセンタキンの使用。
  9. 循環障害に起因するショックの治療剤を製造するためのセンタキンの使用。
JP2012508721A 2009-04-30 2010-04-29 センタキンを用いた新規の治療方法 Active JP5498571B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US17425709P 2009-04-30 2009-04-30
US61/174,257 2009-04-30
PCT/US2010/032942 WO2010127096A2 (en) 2009-04-30 2010-04-29 Novel therapeutic treatments using centhaquin

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2014044799A Division JP5727642B2 (ja) 2009-04-30 2014-03-07 センタキンを用いた新規の治療方法

Publications (3)

Publication Number Publication Date
JP2012525422A JP2012525422A (ja) 2012-10-22
JP2012525422A5 true JP2012525422A5 (ja) 2012-11-29
JP5498571B2 JP5498571B2 (ja) 2014-05-21

Family

ID=43032771

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2012508721A Active JP5498571B2 (ja) 2009-04-30 2010-04-29 センタキンを用いた新規の治療方法
JP2014044799A Active JP5727642B2 (ja) 2009-04-30 2014-03-07 センタキンを用いた新規の治療方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2014044799A Active JP5727642B2 (ja) 2009-04-30 2014-03-07 センタキンを用いた新規の治療方法

Country Status (10)

Country Link
US (2) US20120083447A1 (ja)
EP (1) EP2424529B1 (ja)
JP (2) JP5498571B2 (ja)
CN (2) CN102458399B (ja)
AU (1) AU2010241564B2 (ja)
BR (1) BRPI1013903B1 (ja)
CA (1) CA2759791C (ja)
ES (1) ES2614813T3 (ja)
PL (1) PL2424529T3 (ja)
WO (1) WO2010127096A2 (ja)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010127096A2 (en) 2009-04-30 2010-11-04 Midwestern University Novel therapeutic treatments using centhaquin
CN110354267A (zh) * 2012-08-31 2019-10-22 法尔麦兹公司 用于低血压复苏的方法和组合物
US20170326166A1 (en) * 2014-10-17 2017-11-16 University Of Virginia Patent Foundation Compositions and methods for treating pituitary tumors
AU2019262612A1 (en) * 2018-05-03 2020-11-26 Midwestern University Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
CN117440812A (zh) * 2021-05-11 2024-01-23 法尔麦兹公司 用于治疗冠状病毒病(covid-19)中的急性呼吸窘迫综合征(ards)的药物组合物及方法

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3954987A (en) * 1972-12-22 1976-05-04 Sandoz, Inc. 2-Alkyl-4-substituted amino-quinazolines and nitrates thereof in the treatment of myocardial shock
DE2421382A1 (de) 1974-05-03 1975-11-20 Council Scient Ind Res 1-substituierte 4-(beta-2-chinolylaethyl)- piperazine und deren 1,2,3,4-tetrahydrochinolinanaloge
JPS604186B2 (ja) 1974-05-13 1985-02-01 カウンシル、オブ、サイエンテイフイツク、アンド、インダストリアルリサーチ １―ｍ―トリル―４―（Ｂ―２―キノリエチル）―ピペラジンの製造法
US3983121A (en) 1974-07-01 1976-09-28 Council Of Scientific And Industrial Research 1-Substituted 4-(β-2-quinolylethyl)piperazines and 1,2,3,4-tetrahydroquinolyl-ethyl analogues thereof
DE2557784C2 (de) * 1975-12-22 1986-04-17 Hoechst Ag, 6230 Frankfurt Forskolin, Verfahren zu dessen Gewinnung und diese Verbindung enthaltende pharmazeutische Präparate
US4761417A (en) * 1982-05-14 1988-08-02 Maroko Peter R Compounds, compositions and method of treatments for improving circulatory performance
EP0126327A1 (en) 1983-04-26 1984-11-28 Frank J. Macri Norepinephrine potentiated pharmaceutical composition, ophthalmic solution and kit containing the same
US5055470A (en) 1989-06-01 1991-10-08 Bristol-Myers Squibb Co. Method of treatment of ischemia in brain
US5922681A (en) 1992-09-14 1999-07-13 Warner-Lambert Company Endothelin antagonists
US20040063719A1 (en) * 1998-08-26 2004-04-01 Queen's University At Kingston Combination therapy using antihypertensive agents and endothelin antagonists
US6545048B1 (en) 1999-06-29 2003-04-08 California Institute Of Technology Compositions and methods of treating cancer using compositions comprising an inhibitor or endothelin receptor activity
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US6369114B1 (en) 1999-11-30 2002-04-09 Institute Of Critical Care Medicine Administration of an α2-adrenergic receptor agonist to enhance cardiopulmonary resuscitation
GB0013378D0 (en) 2000-06-01 2000-07-26 Glaxo Group Ltd Use of therapeutic benzamide derivatives
SE0004455D0 (sv) 2000-12-01 2000-12-01 Milos Pekny Method for neuron regeneration in the central nervous system
US6573285B2 (en) 2000-12-21 2003-06-03 Bristol-Myers Squibb Co. Method for preventing or treating pain by administering an endothelin antagonist
US20030232787A1 (en) 2001-05-08 2003-12-18 Dooley David James Combinations of an endothelin receptor antagonist and an antiepileptic compound having pain alleviating properties or analgesic
US20030104976A1 (en) 2001-07-23 2003-06-05 Gudarz Davar Analgesic methods using endothelin receptor ligands
US7030082B2 (en) 2001-09-07 2006-04-18 Nobex Corporation Pharmaceutical compositions of drug-oligomer conjugates and methods of treating disease therewith
US7973064B2 (en) * 2001-11-27 2011-07-05 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating an opiate analgesic
US7351692B2 (en) * 2002-06-19 2008-04-01 The Board Of Trustees Of The University Of Illinois Method and composition for potentiating the antipyretic action of a nonopioid analgesic
JP2006508086A (ja) 2002-10-24 2006-03-09 ザ ボード オブ トラスティーズ オブ ザ ユニバーシティ オブ イリノイ 固形腫瘍を予防および治療するための方法および組成物
GB0226931D0 (en) 2002-11-19 2002-12-24 Astrazeneca Ab Chemical compounds
AU2003280117B2 (en) 2002-11-20 2009-09-10 Newron Sweden Ab Compounds and methods for increasing neurogenesis
CN101005828B (zh) 2004-06-17 2012-01-11 维尔恩公司 用于经粘膜递送活性成分的包含粘膜粘附蛋白和所述活性物质的组合物
WO2008043102A2 (en) 2006-10-06 2008-04-10 Transition Therapeutics Inc. Vasoactive intestinal polypeptide compositions
KR101388087B1 (ko) 2005-08-31 2014-04-25 유니버시티 오브 테네시 리서치 파운데이션 선택적 안드로겐 수용체 조절제를 이용한 신장 질환, 화상,부상 및 척수 손상의 치료 방법
JP4976412B2 (ja) 2005-12-01 2012-07-18 ベー・エル・アー・ハー・エム・エス・ゲーエムベーハー エンドセリン、エンドセリンアゴニスト及びアドレノメジュリンアンタゴニストによる危篤患者の診断及び治療のための方法
AU2007230887A1 (en) 2006-03-23 2007-10-04 Amylin Pharmaceuticals, Inc. Endothelin and endothelin receptor agonists in the treatment of metabolic diseases
US20100189802A1 (en) 2007-08-21 2010-07-29 Scott And White Memorial Hospital And Scott, Sherwood, And Brindley Foundation Method for treatment of vascular hyperpermeability
US8623823B2 (en) 2007-08-21 2014-01-07 Midwestern University Methods for treatment of stroke or cerebrovascular accidents using an ETB receptor agonist
CN101374259B (zh) 2007-08-22 2012-08-08 华为技术有限公司 实现多媒体彩铃和多媒体彩像业务的方法和装置
EP2165706A1 (en) 2008-09-18 2010-03-24 BioAlliance Pharma Treating Inflammatory Pain in Mucosa of the Oral Cavity Using Mucosal Prolonged Release Bioadhesive Therapeutic Carriers.
BRPI1013904A2 (pt) 2009-04-30 2016-07-19 Univ Midwestern método e composição para tratar cetoacidose diabética
WO2010127096A2 (en) 2009-04-30 2010-11-04 Midwestern University Novel therapeutic treatments using centhaquin
CA2801934A1 (en) 2010-06-17 2011-12-22 Janssen Pharmaceutica Nv Cyclohexyl-azetidinyl antagonists of ccr2
KR101418941B1 (ko) 2011-04-04 2014-07-15 서울대학교병원 엔도텔린을 유효성분으로 함유하는 허혈성질환 치료용 조성물
CN110354267A (zh) 2012-08-31 2019-10-22 法尔麦兹公司 用于低血压复苏的方法和组合物
JP6928450B2 (ja) 2013-07-08 2021-09-01 ミッドウェスタン ユニバーシティ エンドセリンｂ受容体アゴニストを用いた、神経精神疾患を治療するための組成物及び方法
AU2019262612A1 (en) 2018-05-03 2020-11-26 Midwestern University Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin

Similar Documents

Publication Publication Date Title
JP2013525444A5 (ja)
HRP20171648T1 (hr) Supstituirani piperidil-etil-pirimidin kao inhibitor grelin-o-acil-transferaze
JP2013032389A5 (ja)
JP2015501783A5 (ja)
JP2010522242A5 (ja)
JP2013518107A5 (ja)
JP2016510326A5 (ja)
MD4736C1 (ro) Compus policiclic de carbamoilpiridonă şi utilizarea farmaceutică a acestuia
JP2013542247A5 (ja)
JP2012144574A5 (ja)
UA109991C2 (xx) Карбаматні сполуки, їх отримання і застосування
JP2015516419A5 (ja)
JP2011518833A5 (ja)
EA201490419A1 (ru) Соединения для лечения и профилактики респираторного синцитиального вирусного заболевания
JP2014507477A5 (ja)
JP2012092110A5 (ja)
JP2013520405A5 (ja)
JP2010222367A5 (ja)
MX2012000488A (es) Terapia de combinacion para el tratamiento de la diabetes.
JP2013507408A5 (ja)
JP2012525422A5 (ja)
RU2013150861A (ru) Фармацевтическая композиция, содержащая производные глутаримидов, и их применение для лечения эозинофильных заболеваний
DE602007014206D1 (de) Neuartige serotonin-wiederaufnahmehemmer als arzneimittel mit peripheriesystem-beschränkter aktivität
JP2012516348A5 (ja)
JP2014148552A5 (ja)